Login to Your Account



Five Prime protein beefs rep via GSK license deal; respiratory bid chuffs on

By Randy Osborne
Staff Writer

Friday, July 15, 2016

Five Prime Therapeutics Inc.'s respiratory diseases pact with GSK bore fruit, putting $1.5 million in the pocket of the former by way of a license option fee, with the promise of more if the protein on the table hits milestones.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription